Kunming Biomed International (KBI) announces the hiring of Noel Miranda, DVM, as Chief Veterinarian. "The appointment of Dr. Miranda demonstrates KBI's commitment to striving the utmost care and highest animal welfare standard. By recruitment of the Chief Veterinarian, KBI’s animal use and care program will be greatly strengthened ", says Dr. Bob Zhang, CEO of KBI. Dr. Noel Miranda brings to KBI over 30 years’ experience with various species of laboratory animals. He is a pioneering staff at a Japanese NHP Quality Control Facility and GLP-compliant CRO in the Philippines where he supported in its AAALAC accreditation. He is the founding President of the Philippine Association for Laboratory Animal Science (PALAS), and the first author of the Philippine Code of Practice for the Care and Use of Laboratory Animals. He obtained laboratory animal certifications from Japan and is currently advisor of the World Veterinary Association. He has a MSc in Laboratory Animal Science, Royal Veterinary College, University of London. In KBI, Dr. Noel Miranda will direct the operations of its nonhuman primate (NHP) veterinary care program, personnel, and facilities; paly the primary role of the Institutional Attending Veterinarian with oversight and direction of all animal facilities; and take the ultimate responsibility to ensure that KBI’s institutional animal care, welfare, and use program is implemented in a manner that meets the highest international regulatory animal care and use standards and ethical governance.
Kunming Biomed International (KBI) has developed and characterized a large scale of high fat diet (HFD)-induced NHP models of metabolic diseases and liver diseases including steatosis, NASH and fibrosis. More than 1500 male cynomolgus monkeys have been fed with HFD over a period of 1-6 years and majority of them have developed obesity and diabetic phenotypes as well as progressed to metabolic complications including CKD, CVD and metabolic liver diseases. MRI-based liver fat quantification and percutaneous liver biopsy have exposed significant numbers of monkeys that manifested the full spectrum of non-alcoholic fatty liver disease (NAFLD) ranging from steatosis (more than 800 monkeys) to NASH (more than 800 monkeys) and fibrosis (more than 800 monkeys). KBI will present this work in this year’s The Liver Meeting® 2017 of American Association for the Study of Liver Diseases (AASLD), hold in Washington D.C., USA, October 20 -24, 2017. KBI’s meeting abstract “Development and Characterization of High Fat Diet-induced Non-human Primate Models of Liver Diseases: Steatosis, NASH and Fibrosis” has been honorably appointed as a Presidential Poster of Distinction for presentation at the meeting, ranking to the top 10% of scored poster abstracts by the Scientific Program Committee of AASLD. KBI’s poster will receive special recognition in the poster hall during the presentation day. Welcome to visit our poster during the meeting or search our abstract from the journal of HEPATOLOGY in its October supplement. Our poster presentation details are below: Publication Number: 1959 Session Date and Time: October 23, 2017 from 8:00am to 5:30pm Session: Steatohepatitis: Experimental Location: Hall D, Walter E. Washington Convention Center, Washington D.C. USA Also, KBI’s poster is also accessible from AASLD meeting’s ePoster. The poster QR is:
On March 24th , 2017, Kunming Biomed International (KBI) received a letter from AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) that KBI’s animal care and use program is granted continuously full accreditation following site visit and program review. The AAALAC International Council on Accreditation recognizes KBI’s effort, contribution and participation in providing and maintaining an excellent program of laboratory animal care and use.
The 56th SOT Annual Meeting which was organized by the Society of Toxicology took place at the Baltimore Convention Center in Baltimore, USA March 12 to 16, 2017. The SOT Annual Meeting is the largest meeting of its kind and more than 6,700 attendees from all over the world participated in this year’s meeting. This annual event featured a broad range of scientific sessions and a thematic program that provided participants with a unique opportunity to deepen the knowledge in specialized topics in toxicology and interact with world leading institutions and companies in their respective disciplines. KBI participated in the meeting’s grand ToxExpo program to exhibit our full spectrum of capabilities in non-human primate biomedical research services. Our exhibition booth attracted a significant number of attendees interested in preclinical non-human primate translational research.
Kunming Biomed International was awarded the High and New Technology Enterprise Certificate on 2016 Yunnan Province High and New Technology Enterprises Cultivating Notification and Awarding Ceremony. Yunnan Provincial Science and Technology Department, the Provincial Department of Finance, the Provincial State Taxation Bureau, the Provincial Land Tax Bureau, the Provincial Intellectual Property Office, the Provincial Academy of Sciences and technology, the Provincial Promotion Association for the High and New Technology Enterprises attended the ceremony.